CompanyGraph
What stands out
- Earnings significantly exceed cash generation
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$408.61M, lower than 95% of all stocks globally
- PositionGross margin is 7.7%, lower than 95% of its Biotechnology peers (median 78%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
8.54%
Annual Rate
CNY 0.38Paid unknown
Payout Ratio
137.9%High
Payback Period
11.2 yr
Last Ex-Dividend
Jul 23, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
7.41BCNY1.10B · vs all stocks (USD)
Trailing P/E
15.64xvs Biotechnology peers
Revenue (TTM)
15.60BCNY2.32B · vs all stocks (USD)
Profit Margin
2.94%vs Biotechnology peers
Beta
0.0430xvs all stocks
52-Week Change
-45.34%vs all stocks
Forward Annual Dividend Yield
8.54%vs all stocks
Market Capitalization
7.41BCNY1.10B · vs all stocks (USD)
Enterprise Value
12.64BCNY1.88B · vs all stocks (USD)
Trailing P/E
15.64xvs Biotechnology peers
Forward P/E
6.08xvs Biotechnology peers
Price to Sales (TTM)
0.4665xvs Biotechnology peers
Price to Book (MRQ)
0.8904xvs Biotechnology peers
Enterprise to Revenue
0.8100xvs Biotechnology peers
Enterprise to EBITDA
9.31xvs Biotechnology peers
Gross Margin
7.65%vs Biotechnology peers
Profit Margin
2.94%vs Biotechnology peers
Operating Margin
-1.10%vs Biotechnology peers
Return on Assets (TTM)
1.94%vs Biotechnology peers
Return on Equity (TTM)
5.30%vs Biotechnology peers
Revenue (TTM)
15.60BCNY2.32B · vs all stocks (USD)
Revenue per Share (TTM)
9.39CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-7.40%vs Biotechnology peers
Gross Profit (TTM)
1.93BCNY286.80M · vs all stocks (USD)
EBITDA (TTM)
2.22BCNY329.75M · vs all stocks (USD)
Net Income (TTM)
457.83MCNY68.08M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-17.71%vs Biotechnology peers
Operating Cash Flow (TTM)
151.96MCNY22.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.75BCNY-408.61M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3800CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
8.54%vs all stocks
Trailing Annual Dividend Rate
0.3800CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
8.54%vs all stocks
Payout Ratio
137.88%vs Biotechnology peers
Minority Interest (Equity)
231.52MCNYFY2025 · Dec 31, 2025Revenue
15.90BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
13.27BCNYFY2025 · Dec 31, 2025Gross Profit
2.63BCNYFY2025 · Dec 31, 2025Operating Income
1.29BCNY191.19M · vs all stocks (USD)
Pre-tax Income
1.22BCNYFY2025 · Dec 31, 2025Income Tax Expense
248.21MCNYFY2025 · Dec 31, 2025Net Income
970.04MCNYFY2025 · Dec 31, 2025EBIT
1.30BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.22BCNYFY2025 · Dec 31, 2025Research & Development
184.12MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
310.67MCNYFY2025 · Dec 31, 2025Other Operating Expenses
125.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
44.93MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
80.71MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5892CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5892CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.66BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.66BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
970.04MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.85MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
798.07MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.24BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.36BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
970.04MCNYFY2025 · Dec 31, 2025Other Non-cash Items
83.98MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.82MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-215.12MCNYFY2025 · Dec 31, 2025Capital Expenditures
-2.04BCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.57BCNYFY2025 · Dec 31, 2025Sale of Investments
3.68BCNYFY2025 · Dec 31, 2025Other Investing Activity
-492.41MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.41BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
5.04BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.97BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-726.54MCNYFY2025 · Dec 31, 2025Other Financing Charges
958.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.30BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.66BSharesUpdated Aug 20, 2026Float Shares
932.88MSharesUpdated Aug 20, 2026% Held by Insiders
48.36%vs all stocks
% Held by Institutions
4.39%vs all stocks
Total Cash (MRQ)
1.11BCNY164.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6680CNYUpdated Aug 20, 2026Total Debt (MRQ)
6.13BCNY911.05M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.7293xvs Biotechnology peers
Current Ratio (MRQ)
0.9710xvs Biotechnology peers
Book Value per Share (MRQ)
4.92CNYUpdated Aug 20, 2026Total Assets
17.24BCNY2.56B · vs all stocks (USD)
Total Current Assets
5.85BCNYFY2025 · Dec 31, 2025Total Liabilities
8.79BCNYFY2025 · Dec 31, 2025Total Non-current Assets
11.39BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.66BCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.13BCNYFY2025 · Dec 31, 2025Cash
1.31BCNYFY2025 · Dec 31, 2025Cash Equivalents
881.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.19BCNYFY2025 · Dec 31, 2025Other Short-term Investments
462.07KCNYFY2025 · Dec 31, 2025Accounts Receivable
625.62MCNYFY2025 · Dec 31, 2025Inventory
2.21BCNYFY2025 · Dec 31, 2025Accounts Payable
1.47BCNYFY2025 · Dec 31, 2025Short-term Debt
3.81BCNYFY2025 · Dec 31, 2025Other Current Liabilities
113.84MCNYFY2025 · Dec 31, 2025Long-term Debt
2.43BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.66BCNYFY2025 · Dec 31, 2025Retained Earnings
1.64BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.45BCNY1.26B · vs all stocks (USD)
52-Week Low
4.26CNYUpdated Aug 20, 202652-Week High
8.55CNYUpdated Aug 20, 202652-Week Change
-45.34%vs all stocks
Beta
0.0430xvs all stocks
50-Day MA
4.63CNYUpdated Aug 20, 2026200-Day MA
6.28CNYUpdated Aug 20, 2026Avg 10-Day Volume
20.50MSharesUpdated Aug 20, 2026Avg 30-Day Volume
22.73MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.2800CNYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 7.7%, lower than 95% of its Biotechnology peers (median 78%)Significant
Gross margin: 0.08Industry median: 0.78Industry P5: 0.18Peers compared: 197
Current ratio is 0.97×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.97Industry median: 5.50Industry P5: 0.97Peers compared: 197
Price-to-book is 0.89×, lower than 95% of its Biotechnology peers (median 5.36×)Notable
Price-to-book: 0.89Industry median: 5.36Industry P5: 1.40Peers compared: 197
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 68,083,411.531Operating Cash Flow (USD, TTM): 22,598,352.298
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 1.38Dividend per Share: 0.38Earnings per Share: 0.28
Financial Health
Altman Z-Score 1.79: grey zoneSignificant
Altman Z-Score: 1.79
High earnings qualityNotable
Earnings Quality Score: 0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$408.61M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -408,607,416.66Global P5: -219,013,500
Revenue is $2.32B, above the global median of $520.53MNotable
Revenue (USD): 2,320,009,091.881Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Procept BioRobotics Corporation
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hansol IONES Co. Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book Value
Chengdu Guibao Science & Technology Co., Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book Value
Yapp Automotive Parts Co., Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book Value